1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends

The Ebola Report: 2014 Epidemic And R&D Drug Prospects

  • November 2014
  • 115 pages
  • Visiongain
Report ID: 2575558

Summary

Table of Contents

Please note: The license is valid for 12 months from the date the report is sent.


Report Details
The Ebola Report - new study showing you trends and R&D progress
What opportunities are there in a market for Ebola diagnostics, prevention, and treatment? What are the commercial prospects for this market and related technologies? Visiongain’s new report shows market potential for products and other trends, discussing data, opportunities and prospects.

Our new 115 page report provides 40 tables, charts, and graphs. Discover the R&D prospects of products in the pipeline and their future market potential. Our new study lets you assess the leading candidates in the race for entry into the market for Ebola diagnostics, vaccines, and treatments. You will see interviews, trends, and opportunities that may arise.

Future outlook and other analyses show you commercial prospects
Our new study provides you with original analyses, with business outlooks and developments. Discover qualitative analyses, product profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Prof. Sunetra Gupta, Professor of Theoretical Epidemiology, University of Oxford
- Dr Derek Gatherer, Division of Biomedical and Life Sciences, Lancaster University

You find prospects for the R&D pipeline of key submarkets
What is happening in the R&D pipeline for Ebola diagnostics, drugs and vaccines? You see developmental trends, gaining insight into the current products in development. In addition to analyses of currently used Ebola pharma/Medtech products, you see analyses for the pipeline of these three product categories:
- Ebola diagnostics
- Ebola treatments
- Ebola vaccines

Drugs that can significantly reduce the high mortality rate associated with infections with the Ebola virus whilst reducing the many grievous symptoms will achieve success. Vaccines aimed at protecting front-line healthcare workers treating patients infected with the Ebola virus will prove successful and financially viable to developers and manufacturers

Our investigation shows business research and analyses with individual product evaluations and discussions. You find the dynamics of the industry and assess its potential growth, seeing agents likely to achieve the most success.

See insightful analysis for products
What are the characteristics of the most promising drugs and vaccines being developed or tested to treat or prevent Ebola? How will promising products currently in the pipeline perform once they are launched? Our study profiles promising Ebola drugs including these:
- ZMapp
- Brincidofivir
- BCX4430
- AVI-7537
- Lamivudine
- Favipiravir
- TKM-Ebola

You will see what is happening, understanding trends, challenges and opportunities. Discover features and profiles for Ebola vaccines currently under development. These include:
- VesiculoVax
- GSK’s ChAd vaccine
- New Link Genetic Corp’s rVSV vaccine
- Johnson & Johnson/ Bavarian Nordic AdVac/ MVA-BN Technology-based vaccine

What are the prospects for the various regions and countries?
Which countries are most at risk? Which countries are best prepared to tackle potential cases of Ebola? Regulatory approvals and the trends being observed for some products getting fast tracked will play a crucial role in shaping the future of the market for Ebola drugs and vaccines. Our analyses show a rapid uptake for products targeting the Ebola virus and Ebola virus disease on the back of the devastation caused by the Ebola virus disease outbreak in West Africa in 2014. In particular, the countries in North America and Europe will look to stock up on Ebola drugs and vaccines to counter the risk of Ebola virus disease spreading into the region. Furthermore, the potential threat of the Ebola virus be

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Infectious Disease Testing Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 59500
  • Industry report
  • May 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

Virology and Bacteriology Testing Market 2021: A 68-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 59500
  • Industry report
  • June 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

Automated Microbiology Market 2021: A 68-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification

  • $ 52500
  • Industry report
  • June 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides granular data and analysis not available from any other published source. The survey is designed to help current suppliers and potential market ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.